BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15737527)

  • 1. Caspofungin as treatment for Candida glabrata hip infection.
    Lejko-Zupanc T; Mozina E; Vrevc F
    Int J Antimicrob Agents; 2005 Mar; 25(3):273-4. PubMed ID: 15737527
    [No Abstract]   [Full Text] [Related]  

  • 2. Candida glabrata endophthalmitis treated successfully with caspofungin.
    Sarria JC; Bradley JC; Habash R; Mitchell KT; Kimbrough RC; Vidal AM
    Clin Infect Dis; 2005 Mar; 40(5):e46-8. PubMed ID: 15714407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin in combination with amphotericin B against Candida glabrata.
    Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine.
    Dumaine V; Eyrolle L; Baixench MT; Paugam A; Larousserie F; Padoin C; Tod M; Salmon D
    Int J Antimicrob Agents; 2008 Apr; 31(4):398-9. PubMed ID: 18242959
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of liposomal amphotericin B refractory Candida glabrata fungaemia in a patient undergoing a stem cell transplantation.
    Veldman BA; Verweij PE; Blijlevens NM
    Neth J Med; 2006 Apr; 64(4):127-9. PubMed ID: 16609161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.
    Lye DC; Hughes A; O'Brien D; Athan E
    Eur J Clin Microbiol Infect Dis; 2005 Nov; 24(11):753-5. PubMed ID: 16283214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole stability in cement spacers.
    Denes E; Fiorenza F; Saint-Marcoux F; Megherbi M; Dupon M; Weinbreck P
    Med Mal Infect; 2012 Nov; 42(11):567-8. PubMed ID: 23044087
    [No Abstract]   [Full Text] [Related]  

  • 8. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
    Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
    Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
    [No Abstract]   [Full Text] [Related]  

  • 9. Candida inferior vena cava filter infection and septic thrombophlebitis.
    Meda MS; Lopez AJ; Guyot A
    Br J Radiol; 2007 Feb; 80(950):e48-9. PubMed ID: 17495055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
    Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
    Cota J; Carden M; Graybill JR; Najvar LK; Burgess DS; Wiederhold NP
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3926-8. PubMed ID: 16940061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida glabrata prosthetic hip infection.
    Bartalesi F; Fallani S; Salomoni E; Marcucci M; Meli M; Pecile P; Cassetta MI; Latella L; Bartoloni A; Novelli A
    Am J Orthop (Belle Mead NJ); 2012 Nov; 41(11):500-5. PubMed ID: 23431513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance.
    Agnelli C; Guinea J; Valerio M; Escribano P; Bouza E; Muñoz P
    Rev Esp Quimioter; 2019 Aug; 32(4):395-397. PubMed ID: 31327188
    [No Abstract]   [Full Text] [Related]  

  • 14. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
    Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
    Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
    Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
    Krogh-Madsen M; Arendrup MC; Heslet L; Knudsen JD
    Clin Infect Dis; 2006 Apr; 42(7):938-44. PubMed ID: 16511756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of candidemia on caspofungin therapy: a case report.
    Cheung C; Guo Y; Gialanella P; Feldmesser M
    Infection; 2006 Dec; 34(6):345-8. PubMed ID: 17180591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole for candidosis: an important addition?
    Graybill JR
    Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
    [No Abstract]   [Full Text] [Related]  

  • 20. Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report.
    Yamada SM; Tomita Y; Yamaguchi T; Matsuki T
    J Med Case Rep; 2016 Nov; 10(1):316. PubMed ID: 27821139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.